Investors

Cereno Scientific is a pioneering clinical-stage biotech company focusing on developing innovative, effective, and safe treatments for patients affected by rare and common cardiovascular disease where great unmet medical needs persist. Cardiovascular disease is the number one cause of death globally, killing nearly twice as many people as cancer. The term cardiovascular disease includes all diseases which involve the heart and/or the blood vessels. A majority of the complications associated with cardiovascular disease are caused by a blocking blood clot in a vein or artery in the body. Many people affected by a blood clot have as a consequence, for example, a heart attack, secondary heart failure, cardiac arrhythmias, stroke or other direct manifestations of blood clots in lungs or peripheral vessels.

Cereno's pipeline comprises:

• Drug candidate CS1, a HDAC inhibitor with epigenetic effects, in Phase II is being developed as a treatment of the rare disease pulmonary arterial hypertension (PAH).
• Drug candidate CS014, a novel HDAC inhibitor with epigenetic effects, being developed as a treatment for thrombosis prevention, currently evaluated in a Phase I, first-in-human trial.
• Drug candidate CS585, a novel IP Receptor Agonist, in preclinical phase. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.

Cereno Scientific's B share (CRNO B) has been traded on Nasdaq First North Growth Market since June 2023, when a move from Spotlight Stock Market was completed where the company had been listed since June 2016.